SRRA stock: buy or sell?

SRRA stock price: $0.24 -4.00% At close on November 15th, 2019

Updated on:
November 15th, 2019


Shares of Sierra Oncology collapsed a hair-raising -4.00% and closed at $0.24. On November/7 SRRA plunged a chilling -40.00%. On November/6 SRRA skyrocketed an extraordinary 5.71%.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally.

Should I buy SRRA stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

None of our preferred buy setups matches with Sierra Oncology stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean SRRA will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Sierra Oncology stock a buy?

Financial institutions and banks publish stock ratings everyday. Unfortunately, we couldn't detect any rating for SRRA stock for the last month.

SRRA stock analysis

Daily outlook

Sierra Oncology shares collapsed -4.00% to $0.24 yesterday.

Sierra Oncology shares collapsed -4.00% to $0.24 yesterday. SRRA marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $0.35 would break this short term down trend and open possibilities for reversing this situation.

SRRA stock chart (daily)

Weekly outlook

Shares of Sierra Oncology ended this week at $0.24 and collapsed a scary -7.69%. Late October SRRA climbed an amazing 9.09% in just one week.

Sierra Oncology is now in fresh lows to find new supports after lossing the support. Since price and 40-weeks moving average lines crossed down late March, SRRA fell $-1.63 per share (-87.17%). Stocks under the 40-weeks moving average line are usually not recommended for average traders.

SRRA stock chart (weekly)

SRRA stock price history

SRRA IPO was on July 16th, 2015 at $28.68 per share1. Since then, SRRA stock sliced a -99.20%, with a yearly average of -24.80%.

1: Adjusted price after possible price splits or reverse-splits.

SRRA stock historical price chart

SRRA stock reached 52-week highs on March at $2.01, and all-time highs 2015-07-16 with a price of 33.75.

SRRA stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price forecast for Sierra Oncology stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Sierra Oncology didn't meet the estimates of the experts and posted a rough EPS of $-0.19 per share when experts were expecting $-0.21.
SRRA earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to , last anual sales report draw of to million dollars. When comparing vs , , profit margin (that is, the net income divided by revenues) a to .

SRRA annual Sales and Income evolution

Quarterly financial results

Reported quarter income marked $-14.28 M with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Sierra Oncology sales marked a tight movement and stayed steady a nan%. Looking back to recent quarterly results, Sierra Oncology posted 7 negative quarters in a row.
SRRA quarterly Sales and Income evolution

Sierra Oncology ownership

When you are planning to invest in a stock, it's always worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Sierra Oncology, 1.38% of all outstanding shares are owned by its staff.

In case of Sierra Oncology stock, 67.14% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SRRA stock account 0.00%, no big difference from last month.

For a better understanding, the following table shows ownership data compared to other related stocks:

Market cap$17.9 M$62.6 M$191.1 M
Total shares74.7 M11.6 M49.4 M
Float shares60.6 M5.8 M41.4 M
  - Institutional holdings (%)67.1%53.7%72.8%
  - Insider holdings (%)1.4%20.9%0.2%
Shares in short selling0.0%0.0%0.0%

SRRA summary

Friday, November 15th, 2019
Day range$0.23 - $0.28
Previous close$0.25
Session gain-4.00%
Average true range$0.03
50d mov avg$0.35
100d mov avg$0.42
200d mov avg$0.93
Daily patternlb06a
Weekly pattern lt01c

Sierra Oncology performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Sierra Oncology performance to Champions Oncology and Pieris Pharmaceuticals:
SRRASierra Oncology-44.19%-83.56%-85.96%
CSBRChampions Oncolog...-12.78%-36.59%-56.57%
PIRSPieris Pharmaceut...-22.60%7.80%11.21%

Sierra Oncology competitors

Defining a list of competitors for Sierra Oncology it's difficult. We selected 2 public companies that are related to and can be considered as competitors of Sierra Oncology: